Factor VIII inhibitor bypassing fraction (Specialist drug)

How it works

It contains activated and non-activated clotting factors that bypass the need for factor VIII or IX, promoting thrombin generation and clot formation despite the presence of inhibitors.

Prescribing in practice

• It carries a risk of thromboembolic events and disseminated intravascular coagulation, so dosing limits should be respected and it must not be combined with antifibrinolytics without specialist advice or used concurrently with emicizumab without expert guidance owing to thrombotic microangiopathy risk.
• It should be used under haemophilia-centre supervision because routine coagulation tests do not reliably guide dosing.
• As a plasma-derived product, viral-safety considerations and hepatitis immunisation apply.

Monitoring

Monitor clinically for haemostatic response and for signs of thrombosis or disseminated intravascular coagulation rather than relying on standard coagulation assays.

Counselling the patient

• Report chest pain, breathlessness, leg swelling or other signs of a clot urgently.
• Tell every clinician you are on an inhibitor-bypassing product, especially if you also receive emicizumab.
• Use this product only as directed by your haemophilia centre and keep treatment records.

Evidence & guidelines

Bypassing agents are a recognised standard for managing bleeding in inhibitor patients, with thrombotic and combination-therapy cautions highlighted following emicizumab safety experience.